630 related articles for article (PubMed ID: 33155698)
1. Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A; Wang W; Liu G; Wang X; Xian W; McKeon F; Foster J; Zhou J; Zhang R
Med Res Rev; 2021 Mar; 41(2):961-1021. PubMed ID: 33155698
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms and therapeutic targets in neuroblastoma.
Johnsen JI; Dyberg C; Fransson S; Wickström M
Pharmacol Res; 2018 May; 131():164-176. PubMed ID: 29466695
[TBL] [Abstract][Full Text] [Related]
4. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
5. Targeting RAS in neuroblastoma: Is it possible?
Lin L; Miao L; Lin H; Cheng J; Li M; Zhuo Z; He J
Pharmacol Ther; 2022 Aug; 236():108054. PubMed ID: 34915055
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma treatment in the post-genomic era.
Esposito MR; Aveic S; Seydel A; Tonini GP
J Biomed Sci; 2017 Feb; 24(1):14. PubMed ID: 28178969
[TBL] [Abstract][Full Text] [Related]
7. Therapy resistance in neuroblastoma: Mechanisms and reversal strategies.
Zhou X; Wang X; Li N; Guo Y; Yang X; Lei Y
Front Pharmacol; 2023; 14():1114295. PubMed ID: 36874032
[TBL] [Abstract][Full Text] [Related]
8. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
9. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
10. Research progress of neuroblastoma related gene variations.
Cao Y; Jin Y; Yu J; Wang J; Yan J; Zhao Q
Oncotarget; 2017 Mar; 8(11):18444-18455. PubMed ID: 28055978
[TBL] [Abstract][Full Text] [Related]
11. Chromosome Imbalances in Neuroblastoma-Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future.
Guan J; Hallberg B; Palmer RH
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885007
[TBL] [Abstract][Full Text] [Related]
12. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
13. Metabolic protein kinase signalling in neuroblastoma.
Smiles WJ; Catalano L; Stefan VE; Weber DD; Kofler B
Mol Metab; 2023 Sep; 75():101771. PubMed ID: 37414143
[TBL] [Abstract][Full Text] [Related]
14. Recent insights into the biology of neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Delattre O
Int J Cancer; 2014 Nov; 135(10):2249-61. PubMed ID: 25124476
[TBL] [Abstract][Full Text] [Related]
15. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.
Zafar A; Wang W; Liu G; Xian W; McKeon F; Zhou J; Zhang R
Cancer Lett; 2021 Jan; 496():16-29. PubMed ID: 33007410
[TBL] [Abstract][Full Text] [Related]
16. Targeting ALK in neuroblastoma--preclinical and clinical advancements.
Carpenter EL; Mossé YP
Nat Rev Clin Oncol; 2012 May; 9(7):391-9. PubMed ID: 22585002
[TBL] [Abstract][Full Text] [Related]
17. Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.
Bettinsoli P; Ferrari-Toninelli G; Bonini SA; Prandelli C; Memo M
BMC Cancer; 2017 May; 17(1):352. PubMed ID: 28525978
[TBL] [Abstract][Full Text] [Related]
18. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma.
King D; Yeomanson D; Bryant HE
J Pediatr Hematol Oncol; 2015 May; 37(4):245-51. PubMed ID: 25811750
[TBL] [Abstract][Full Text] [Related]
19. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L; Caron H; Geoerger B; Eggert A; Schleiermacher G; Brock P; Valteau-Couanet D; Chesler L; Schulte JH; De Preter K; Molenaar J; Schramm A; Eilers M; Van Maerken T; Johnsen JI; Garrett M; George SL; Tweddle DA; Kogner P; Berthold F; Koster J; Barone G; Tucker ER; Marshall L; Herold R; Sterba J; Norga K; Vassal G; Pearson AD
Expert Opin Drug Discov; 2017 Aug; 12(8):801-811. PubMed ID: 28604107
[TBL] [Abstract][Full Text] [Related]
20. RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.
Singhal SS; Nagaprashantha L; Singhal P; Singhal S; Singhal J; Awasthi S; Horne D
Pharm Res; 2017 Aug; 34(8):1673-1682. PubMed ID: 28386633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]